Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma - guidance (TA465)

National Institute for Health and Care Excellence - NICE
Publication date:
09 August 2017


Evidence-based recommendations on olaratumab (Lartruvo) plus doxorubicin for advanced soft tissue sarcoma in adults.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: More evidence on olaratumumab is being collected, until December 2020. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

Commercial arrangement

There is a managed access agreement, which includes a commercial access agreement for olaratumumab. Contact UKPricing@lilly.com for details.